AstraZeneca Collaborates with Schrödinger to Utilize its Molecule-Modeling Platform for Drug Discovery

 AstraZeneca Collaborates with Schrödinger to Utilize its Molecule-Modeling Platform for Drug Discovery

AstraZeneca Collaborates with Schrödinger to Utilize its Molecule-Modeling Platform for Drug Discovery

Shots:

  • AstraZeneca enters into an agreement with Schrödinger to deploy Schrödinger’s advanced computing platform for accelerating its drug discovery efforts
  • AstraZeneca will utilize predictive physics-based modeling and machine learning platform to identify new therapies including an improvement in the design of its compounds 
  • Schrödinger’s platform predicts the potency of a molecule binding to a target protein and optimizes its chemical properties and reduces the number of compounds to be synthesized before settling on a lead candidate

Click here to­ read full press release/ article | Ref: Schrödinger | Image: Manufacturers Monthly

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post